Literature DB >> 9755888

Overexpression of human intestinal oligopeptide transporter in mammalian cells via adenoviral transduction.

C P Hsu1, J M Hilfinger, E Walter, H P Merkle, B J Roessler, G L Amidon.   

Abstract

PURPOSE: Our goals are to establish an in vitro screening system and to evaluate a new approach in improving oral absorption of peptides and peptide-like drugs by overexpression of the human intestinal oligopeptide transporter (hPepT1). This study characterizes the expression of hPepT1 in human intestinal Caco-2 cells, rat intestinal epithelial cells (IEC-18), and human cervix epithelial cells (Hela) after adenoviral transduction.
METHODS: A recombinant replication-deficient adenovirus carrying the hPepT1 gene was made and used as a vector for the expression of hPepT1. The increase in the uptake permeability of cephalexin and Gly-Sar was determined. The effects of time, dose, apical pH, and substrate specificity were evaluated.
RESULTS: A significant increase in the uptake permeability of Gly-Sar and cephalexin was found in all three cell lines after viral transduction. The increase of Gly-Sar permeability in Hela. IEC-18, and Caco-2 cells was 85-, 46-, and 15-fold respectively. Immunoblotting using an antibody against hPepT1 detected high levels of a 85-98-kDa protein in all three infected cell lines. Substrate permeability was dependent on time of infection, inward pH gradients, and multiplicity of infection (MOI). Decreased infectivity and lower hPepT1 expression were observed in differentiated Caco-2 cells. The uptake was inhibited by dipeptides and beta-lactam antibiotics but not amino acids.
CONCLUSIONS: Adenoviral infected Hela cells displayed a pronounced level of hPepT1 expression with a low background and high specificity to dipeptides. These features make this system a useful tool for screening of potential substrates. The success of overexpression of hPepT1 in Caco-2 and IEC-18 cells may lead to a novel approach in improving oral absorption of peptides and peptidornimetic drugs.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  1998        PMID: 9755888     DOI: 10.1023/a:1011993303397

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  22 in total

1.  In vitro permeability through caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system.

Authors:  S Chong; S A Dando; K M Soucek; R A Morrison
Journal:  Pharm Res       Date:  1996-01       Impact factor: 4.200

2.  Immuno-localization of H+/peptide cotransporter in rat digestive tract.

Authors:  H Ogihara; H Saito; B C Shin; T Terado; S Takenoshita; Y Nagamachi; K Inui; K Takata
Journal:  Biochem Biophys Res Commun       Date:  1996-03-27       Impact factor: 3.575

3.  A model system for in vivo gene transfer into the central nervous system using an adenoviral vector.

Authors:  B L Davidson; E D Allen; K F Kozarsky; J M Wilson; B J Roessler
Journal:  Nat Genet       Date:  1993-03       Impact factor: 38.330

4.  Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of beta-lactam antibiotics in the intestine and kidney.

Authors:  H Saito; M Okuda; T Terada; S Sasaki; K Inui
Journal:  J Pharmacol Exp Ther       Date:  1995-12       Impact factor: 4.030

5.  Expression cloning of a mammalian proton-coupled oligopeptide transporter.

Authors:  Y J Fei; Y Kanai; S Nussberger; V Ganapathy; F H Leibach; M F Romero; S K Singh; W F Boron; M A Hediger
Journal:  Nature       Date:  1994-04-07       Impact factor: 49.962

6.  Transport of charged dipeptides by the intestinal H+/peptide symporter PepT1 expressed in Xenopus laevis oocytes.

Authors:  S Amasheh; U Wenzel; M Boll; D Dorn; W Weber; W Clauss; H Daniel
Journal:  J Membr Biol       Date:  1997-02-01       Impact factor: 1.843

7.  Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds.

Authors:  G L Amidon; P J Sinko; D Fleisher
Journal:  Pharm Res       Date:  1988-10       Impact factor: 4.200

8.  Functional expression of intestinal dipeptide/beta-lactam antibiotic transporter in Xenopus laevis oocytes.

Authors:  I Tamai; N Tomizawa; A Kadowaki; T Terasaki; K Nakayama; H Higashida; A Tsuji
Journal:  Biochem Pharmacol       Date:  1994-08-30       Impact factor: 5.858

9.  Human intestinal H+/peptide cotransporter. Cloning, functional expression, and chromosomal localization.

Authors:  R Liang; Y J Fei; P D Prasad; S Ramamoorthy; H Han; T L Yang-Feng; M A Hediger; V Ganapathy; F H Leibach
Journal:  J Biol Chem       Date:  1995-03-24       Impact factor: 5.157

10.  Effect of adenoviral vector infection on cell proliferation in cultured primary human airway epithelial cells.

Authors:  S Teramoto; L G Johnson; W Huang; M W Leigh; R C Boucher
Journal:  Hum Gene Ther       Date:  1995-08       Impact factor: 5.695

View more
  11 in total

1.  Function and immunolocalization of overexpressed human intestinal H+/peptide cotransporter in adenovirus-transduced Caco-2 cells.

Authors:  C P Hsu; E Walter; H P Merkle; B Rothen-Rutishauser; H Wunderli-Allenspach; J M Hilfinger; G L Amidon
Journal:  AAPS PharmSci       Date:  1999

2.  Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs.

Authors:  Duxin Sun; Hans Lennernas; Lynda S Welage; Jeffery L Barnett; Christopher P Landowski; David Foster; David Fleisher; Kyung-Dall Lee; Gordon L Amidon
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

Review 3.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

4.  Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism.

Authors:  Christopher P Landowski; Xueqin Song; Philip L Lorenzi; John M Hilfinger; Gordon L Amidon
Journal:  Pharm Res       Date:  2005-08-24       Impact factor: 4.200

5.  Drug inhibition of Gly-Sar uptake and hPepT1 localization using hPepT1-GFP fusion protein.

Authors:  D Sun; C P Landowski; X Chu; R Wallsten; T E Komorowski; D Fleisher; G L Amidon
Journal:  AAPS PharmSci       Date:  2001

6.  Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach.

Authors:  Sheeba Varghese Gupta; Deepak Gupta; Jing Sun; Arik Dahan; Yasuhiro Tsume; John Hilfinger; Kyung-Dall Lee; Gordon L Amidon
Journal:  Mol Pharm       Date:  2011-09-22       Impact factor: 4.939

7.  Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach.

Authors:  Jing Sun; Arik Dahan; Gordon L Amidon
Journal:  J Med Chem       Date:  2010-01-28       Impact factor: 7.446

8.  Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.

Authors:  Deepak Gupta; Sheeba Varghese Gupta; Arik Dahan; Yasuhiro Tsume; John Hilfinger; Kyung-Dall Lee; Gordon L Amidon
Journal:  Mol Pharm       Date:  2013-01-04       Impact factor: 4.939

9.  A fluorescent hPept1 transporter substrate for uptake screening.

Authors:  Christopher P Landowski; Hyo-kyung Han; Kyung-Dall Lee; Gordon L Amidon
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

10.  Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter.

Authors:  H K Han; D M Oh; G L Amidon
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.